Diffusion Pharmaceuticals Inc Stock News

Claims Related to Use of TSC with Radiotherapy and Chemotherapy for Treatment of Cancer Claims Related to Use of TSC with Radiotherapy and Chemotherapy for Treatment of Cancer

Claims Related to Use of TSC with Radiotherapy and Chemotherapy for Treatment of Cancer Claims Related to Use of TSC with Radiotherapy and Chemotherapy for Treatment of Cancer

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) traded at $0.43 at last check on Monday, November 29, made an upward move of 10.14% on its previous days price. Looking at the stock we see that its previous close was $0.39 and the beta (5Y monthly) reads 1.56 with the days price range being $0.3669 $0.42. In terms Diffusion Pharmaceuticals Inc.s Stock Price Plummeted Recently, But There Might Be Trouble Ahead Read More »

Check these three biotech penny stocks out for your list this month The post Hot Biotech Penny Stocks to Watch As New Variant Creates Volatility appeared first on Penny Stocks to Buy, Picks, News and

Check these three biotech penny stocks out for your list this month The post Hot Biotech Penny Stocks to Watch As New Variant Creates Volatility appeared first on Penny Stocks to Buy, Picks, News and

Equities analysts expect that Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) will post ($0.04) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Diffusion Pharmaceuticals earnings. Diffusion Pharmaceuticals posted earnings per share of ($0.06) in the same quarter last year, which suggests a positive year over year growth rate of []

Diffusion Pharmaceuticals Inc. (DFFN) with the stream of -0.42% also noticed, India LM Funding America, Inc. (LMFA) encountered a rapid change of 0.51% in the last hour of Wednesdays trading The post Trending Stock to Observe: Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), LM Funding America, Inc. (NASDAQ:LMFA) appeared first on Stocks Equity .

Analysts expect Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) to announce ($0.04) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Diffusion Pharmaceuticals earnings. Diffusion Pharmaceuticals reported earnings of ($0.06) per share during the same quarter last year, which would indicate a positive year over year growth rate of 33.3%. The []

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) was the target of a significant growth in short interest in October. As of October 29th, there was short interest totalling 727,800 shares, a growth of 19.4% from the October 14th total of 609,700 shares. Based on an average daily volume of 982,900 shares, the short-interest ratio is presently 0.7 days. []

Second of Three TSC Oxygenation Trials Second of Three TSC Oxygenation Trials

Second of Three TSC Oxygenation Trials Second of Three TSC Oxygenation Trials

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) was the recipient of a significant growth in short interest in the month of October. As of October 29th, there was short interest totalling 727,800 shares, a growth of 19.4% from the October 14th total of 609,700 shares. Based on an average trading volume of 982,900 shares, the days-to-cover ratio is []

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN)’s traded shares stood at 2.34 million during the latest session, with the company’s beta value hitting 1.45. At the last check today, the stock’s price was $0.40, to imply an increase of 2.52% or $0.01 in intraday trading. The DFFN share’s 52-week high remains $1.85, putting it -362.5% down since that … Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Plunging -42.71% In 6 Months – Here’s What To Expect Read More »

With a new year fast approaching, these biotech penny stocks may benefit from the shifting winds in the broader healthcare market. The post 7 Biotech Penny Stocks With Huge Catalysts Coming in 2022 ap

CHARLOTTESVILLE, Va., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel